Patents by Inventor Martin F. Bachmann
Martin F. Bachmann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7452541Abstract: The present invention provides compositions comprising a conjugate of a hapten with a carrier in an ordered and repetitive array, and methods of making such compositions. The conjugates and compositions of the invention may comprise a variety of haptens, including hormones, toxins and drugs, especially drugs of addiction such as nicotine. Compositions and conjugates of the invention are useful for inducing immune responses against haptens, which can use useful in a variety of therapeutic, prophylactic and diagnostic regimens. In certain embodiments, immune responses generated using the conjugates, compositions and methods of the present invention are useful to prevent or treat addiction to drugs of abuse and the resultant diseases associated with drug addiction.Type: GrantFiled: May 10, 2005Date of Patent: November 18, 2008Assignee: Cytos Biotechnology AGInventors: Martin F. Bachmann, Patrik Maurer
-
Patent number: 7279165Abstract: The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising an ordered and repetitive antigen or antigenic determinant array, and in particular an A?1-6 peptide-VLP-composition. More specifically, the invention provides a composition comprising a virus-like particle and at least one A?1-6 peptide bound thereto. The invention also provides a process for producing the conjugates and the ordered and repetitive arrays, respectively. The compositions of the invention are useful in the production of vaccines for the treatment of Alzheimer's disease and as a pharmaccine to prevent or cure Alzheimer's disease and to efficiently induce immune responses, in particular antibody responses. Furthermore, the compositions of the invention are particularly useful to efficiently induce self-specific immune responses within the indicated context.Type: GrantFiled: July 18, 2003Date of Patent: October 9, 2007Assignee: Cytos Biotechnology AGInventors: Martin F. Bachmann, Alain Tissot, Rainer Ortmann, Rainer Lūönd, Matthias Staufenbiel, Peter Frey
-
Patent number: 7138252Abstract: The present invention provides a composition comprising an AP205 virus like particle (VLP) and an antigen. The invention also provides a process for producing an antigen or antigenic determinant bound to AP205 VLP. AP205 VLP bound to an antigen is useful in the production of compositions for inducing immune responses that are useful for the prevention or treatment of diseases, disorders or conditions including infectious diseases, allergies, cancer, drug addiction, poisoning and to efficiently induce self-specific immune responses, in particular antibody responses.Type: GrantFiled: July 14, 2003Date of Patent: November 21, 2006Assignee: Cytos Biotechnology AGInventors: Martin F. Bachmann, Alain Tissot, Paul Pumpens, Indulis Cielens, Regina Renhofa
-
Patent number: 7128911Abstract: The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising an ordered and repetitive antigen or antigenic determinant array, and in particular a RANKL protein, RANKL fragment or RANKL peptide-VLP-array. More specifically, the invention provides a composition comprising a virus-like particle and at least one RANKL protein, RANKL fragment or RANKL peptide bound thereto. The invention also provides a process for producing the conjugates and the ordered and repetitive arrays, respectively. The compositions of the invention are useful in the production of vaccines for the treatment of bone diseases and as a pharmaccine to prevent or cure bone diseases and to efficiently induce immune responses, in particular antibody responses. Furthermore, the compositions of the invention are particularly useful to efficiently induce self-specific immune responses within the indicated context.Type: GrantFiled: November 7, 2002Date of Patent: October 31, 2006Assignee: Cytos Biotechnology AGInventors: Martin F. Bachmann, Patrik Maurer, Gunther Spohn
-
Patent number: 6932971Abstract: The present invention provides compositions comprising a conjugate of a hapten with a carrier in an ordered and repetitive array, and methods of making such compositions. The conjugates and compositions of the invention may comprise a variety of haptens, including hormones, toxins and drugs, especially drugs of addiction such as nicotine. Compositions and conjugates of the invention are useful for inducing immune responses against haptens, which can use useful in a variety of therapeutic, prophylactic and diagnostic regimens. In certain embodiments, immune responses generated using the conjugates, compositions and methods of the present invention are useful to prevent or treat addiction to drugs of abuse and the resultant diseases associated with drug addiction.Type: GrantFiled: July 18, 2003Date of Patent: August 23, 2005Assignee: Cytos Biotechnology AGInventors: Martin F. Bachmann, Patrik Maurer
-
Publication number: 20040141984Abstract: The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising an ordered and repetitive antigen or antigenic determinant array, and in particular an A&bgr;1-6 peptide-VLP-composition. More specifically, the invention provides a composition comprising a virus-like particle and at least one A&bgr;1-6 peptide bound thereto. The invention also provides a process for producing the conjugates and the ordered and repetitive arrays, respectively. The compositions of the invention are useful in the production of vaccines for the treatment of Alzheimer's disease and as a pharmaccine to prevent or cure Alzheimer's disease and to efficiently induce immune responses, in particular antibody responses. Furthermore, the compositions of the invention are particularly useful to efficiently induce self-specific immune responses within the indicated context.Type: ApplicationFiled: July 18, 2003Publication date: July 22, 2004Applicants: Cytos Biotechnology AG, Novartis Pharma AGInventors: Martin F. Bachmann, Alain Tissot, Rainer Ortmann, Rainer Luond, Matthias Staufenbiel, Peter Frey
-
Publication number: 20040076611Abstract: The present invention provides a composition comprising an AP205 virus like particle (VLP) and an antigen. The invention also provides a process for producing an antigen or antigenic determinant bound to AP205 VLP. AP205 VLP bound to an antigen is useful in the production of compositions for inducing immune responses that are useful for the prevention or treatment of diseases, disorders or conditions including infectious diseases, allergies, cancer, drug addiction, poisoning and to efficiently induce self-specific immune responses, in particular antibody responses.Type: ApplicationFiled: July 14, 2003Publication date: April 22, 2004Inventors: Martin F. Bachmann, Alain Tissot, Paul Pumpens, Indulis Cielens, Regina Renhofa
-
Publication number: 20040076645Abstract: The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising an ordered and repetitive antigen or antigenic determinant array, and in particular a ghrelin or ghrelin-derived peptide-array. More specifically, the invention provides a composition comprising a virus-like particle and at least one ghrelin or a ghrelin-derived peptide bound thereto. The invention also provides a process for producing the conjugates and the ordered and repetitive arrays, respectively. The compositions of the invention are useful in the production of vaccines for the treatment of obesity and other disease associated with increased food-uptake or increased body weight and to efficiently induce immune responses, in particular antibody responses. Furthermore, the compositions of the invention are particularly useful to efficiently induce self-specific immune responses within the indicated context.Type: ApplicationFiled: July 18, 2003Publication date: April 22, 2004Inventors: Martin F. Bachmann, Alma Fulurija
-
Publication number: 20040059094Abstract: The present invention provides compositions comprising a conjugate of a hapten with a carrier in an ordered and repetitive array, and methods of making such compositions. The conjugates and compositions of the invention may comprise a variety of haptens, including hormones, toxins and drugs, especially drugs of addiction such as nicotine. Compositions and conjugates of the invention are useful for inducing immune responses against haptens, which can use useful in a variety of therapeutic, prophylactic and diagnostic regimens. In certain embodiments, immune responses generated using the conjugates, compositions and methods of the present invention are useful to prevent or treat addiction to drugs of abuse and the resultant diseases associated with drug addiction.Type: ApplicationFiled: July 18, 2003Publication date: March 25, 2004Inventors: Martin F. Bachmann, Patrik Maurer
-
Publication number: 20040005338Abstract: The invention relates to the finding that virus like particles (VLPs) can be loaded and packaged, respectively, with DNA oligonucleotides rich in non-methylated C and G (CpGs). If such CpG-VLPs are mixed with antigens, the immunogenicity of these antigens are dramatically enhanced. In addition, the T cell responses against the antigens are especially directed to the Th1 type. Surprisingly, no covalent linkage of the antigen to the VLP is required; it is sufficient to simply mix the VLPs with the adjuvants for co-administration. In addition, it was found that VLPs did not enhance immune responses unless they were loaded and packaged, respectively, with CpGs. Antigens mixed with CpG-packaged VLPs may therefore be ideal vaccines for prophylactic or therapeutic vaccination against allergies, tumors and other self-molecules and chronic viral diseases.Type: ApplicationFiled: June 20, 2003Publication date: January 8, 2004Applicant: Cytos Biotechnology AGInventors: Martin F. Bachmann, Wolfgang A. Renner
-
Publication number: 20030091593Abstract: The invention relates to the finding that stimulation of antigen presenting cell (APC) activation using substances such as anti-CD40 antibodies or DNA oligomers rich in non-methylated C and G (CpGs) can dramatically enhance the specific T cell response obtained after vaccination with recombinant virus like particles (VLPs) coupled, fused or otherwise attached to antigens. While vaccination with recombinant VLPs fused to a cytotoxic T cell (CTL) epitope of lymphocytic choriomeningitis virus induced low levels cytolytic activity only and did not induce efficient anti-viral protection, VLPs injected together with anti-CD40 antibodies or CpGs induced strong CTL activity and full anti-viral protection. Thus, stimulation of APC-activation through antigen presenting cell activators such as anti-CD40 antibodies or CpGs can exhibit a potent adjuvant effect for vaccination with VLPs coupled, fused or attached otherwise to antigens.Type: ApplicationFiled: September 16, 2002Publication date: May 15, 2003Applicant: Cytos Biotechnology AGInventors: Martin F. Bachmann, Franziska Lechner, Tazio Storni
-
Publication number: 20020146422Abstract: The invention relates to compositions for the induction of anti-IgE antibodies in order to prevent or inhibit IgE-mediated disorders. The compositions contain carriers foreign to the immunized human or animal coupled to polypeptides containing fragments of the IgE molecule. The fragment of the IgE molecule includes the constant CH1 and/or the CH4 domain of the IgE molecule. The composition is administered to humans or animals in order to induce antibodies specific for endogenous IgE antibodies. These induced anti-IgE antibodies reduce or eliminate the pool of free IgE in the serum. Since many allergic diseases are mediated by IgE, IgE-mediated disorders are ameliorated in treated mammals.Type: ApplicationFiled: July 27, 2001Publication date: October 10, 2002Applicant: Cytos Biotechnology AGInventors: Martin F. Bachmann, Wolfgang A. Renner